Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. - Wikidata - wikimedia - TriplyDB

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.

http://www.wikidata.org/entity/Q38932495

about

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.Oncolytic virotherapy for urological cancers.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.Recent advances of bispecific antibodies in solid tumors.The making of bispecific antibodies A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.

P2860

Q33691823-C1C71EE9-EDA2-4D67-AE2F-6871FEFE0FC3 Q33822560-488F4617-1BFF-4E9E-A590-8530D426ABAB Q34548319-B5304D7F-3B7D-472B-A4EE-E68FDA482E3A Q37582166-8D0D5DD9-14C9-4D3C-833F-08BF454AEE9C Q38554422-DD652ACE-9091-4529-ADAF-50F1416866E6 Q38775158-8881CAAC-49E8-4D28-8BC2-81DD677BD6FF Q38842126-B191BF3F-2A2F-436B-80DB-424204B68481 Q38929801-B641704E-5C3B-4C1D-8F3A-C17EE8ED0702 Q39000185-C6AF2BE0-2778-4A6C-9D62-3C7C832A1B32 Q40176588-EB1BDD29-FB72-4685-89BF-D0AEC2C3A825 Q41696278-75862E10-F2C2-4883-AC6C-0C0FCB2B5B52 Q42323236-F6675190-E376-4996-97E4-587D96370ABB Q47158524-AEF18EF7-439F-491E-B066-CF0DA880280D

P2860

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.

http://www.wikidata.org/entity/Q38932495

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Antibody targeting of HER2/HER ...... inhibition in prostate cancer.

@en

type

label

Antibody targeting of HER2/HER ...... inhibition in prostate cancer.

@en

prefLabel

Antibody targeting of HER2/HER ...... inhibition in prostate cancer.

@en

P1433

Q38932495-2B6EC369-DBDB-45A3-9157-D9582E1C8D1D

P1476

Q38932495-CC3CC315-6237-4C3C-92A2-E034F1CDB8F2

P2093

Q38932495-68F5CED5-F811-4910-A852-025B2DB6F509

Q38932495-B371FA1D-FE08-40D5-BA66-B65862A1A2AD

Q38932495-B86E231A-1833-4F4A-A037-F7C1FBFF4933

P2860

Q38932495-0788F533-5E93-4C50-9B48-42563B035F09

Q38932495-0ED3D80A-EA0E-49F4-B243-5AC9FE3DA1C3

Q38932495-12F9EF51-5247-4BF4-949F-E30F90734F2D

Q38932495-15A9E6F7-0A01-4A4F-B5A5-BD9554719761

Q38932495-1783EE73-5C89-48D7-A0D9-D4F32D966476

Q38932495-19658AD1-B88F-453B-8210-7ABE5B701E9B

Q38932495-200657C1-E78E-4E85-9ED3-87CD6C1FB672

Q38932495-201E2CEE-BDFB-4F5F-9C45-E0F948600411

Q38932495-2CC6E8AB-305C-4224-84ED-7D5E928666F7

Q38932495-35A1C519-9E63-4860-8710-E62E48F5A6F5

P304

Q38932495-181111C1-0D78-4F3A-AB3F-462C048A8ABB

P31

Q38932495-301614B5-CE3F-4608-962D-3600CF3071E6

P356

Q38932495-C7953FDF-2625-4941-867B-121CCD78EE18

P433

Q38932495-D0C8E4B1-99E4-4BFE-84BB-2083C1880B48

P478

Q38932495-70122DC2-43AF-4523-B1DF-879A4F5CECA7

P50

Q38932495-4CDD1B09-8370-43A3-ACDB-672733686AAA

Q38932495-59884DB8-F1FA-4B94-90AA-D8299C0BDC56

P577

Q38932495-D0F83FD6-2EA2-493F-85FC-CAC04A3FE732

P5875

Q38932495-0A20C85E-4CEE-41D1-AC92-2E95D3F21459

P698

Q38932495-3C19964D-2BB4-47D1-BCD4-FA55BD7B365D

P356

P1433

International Journal of Cancer

P1476

Antibody targeting of HER2/HER ...... inhibition in prostate cancer.

@en

P2093

Dongyoung Kim

http://www.w3.org/2001/XMLSchema#string

Jayakumar S Poovassery

http://www.w3.org/2001/XMLSchema#string

Jeffrey C Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Humanization of an anti-p185HER2 antibody for human cancer therapy

Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Untangling the ErbB signalling network

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway

Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

P304

267-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.29378

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269188856

http://www.w3.org/2001/XMLSchema#string

P698

25471734

http://www.w3.org/2001/XMLSchema#string